GENB
NASDAQGenerate Biomedicines Inc.
$14.46-1.32 (-8.37%)
Generate Biomedicines Inc. (GENB) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for GENB, including 6 press releases and news items and 1 SEC filing. The most recent was published Oct 30, 2026.
Price$14.46-1.32 (-8.37%)
01:15 PM07:45 PM
News · 26 weeks22+200%
2026-05-032026-10-25
Mix1590d
- Other7(47%)
- SEC Filings6(40%)
- Dividends1(7%)
- Insider1(7%)
Latest news
25 items- PR2027 Could Finally Be the Year Cancer Is on the Ropes!DENVER, Oct. 29, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) As 2027 approaches, developments across the United States, Europe and Asia are giving patients, researchers and healthcare markets new reasons to pay attention. Artificial intelligence is helping scientists investigate treatments and connect medical knowledge. Clinical trials are showing survival gains in difficult cancers. Laboratory researchers are exploring ways to make cancer cells manufacture toxic compounds inside themselves and to guide malignant cells toward a more normal state. These advances are at different stages of development. Together, they illustrate the expanding range of approaches researchers are bringin
- SECSEC Form 144 filed by Generate Biomedicines Inc.144 - Generate Biomedicines, Inc. (0002100782) (Subject)
- PRGenerate Biomedicines to Participate in November Investor ConferencesSOMERVILLE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced that members of its management team will participate in presentations at the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference, Boston, Massachusetts: Monday, Nov. 9 at 1 p.m. ETJefferies Global Healthcare Conference, London, UK: Monday, Nov. 16 at 10:30 a.m. ET To access live webcasts of Generate’s presentations, please visit the "Events & Presentations" page within the Investors section of Generate’s website at https://investors.generatebiomedicines.com. A replay of the webcasts will be available on Generate’s website for 90 day
- PRAI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next TestNews Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Bost
- PRGenerate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesCollaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to nearly $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third The agreement will broaden Zealand Pharma’s modality capabilities beyond peptides while extending The Generate Platform into obesity and other metabolic diseases SOMERVILLE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced a m
- PRZealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic DiseasesPress release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functionsGenerate will receive USD 30 million up-front, up to USD 35 million in early preclinical milestones, and a total of nearly USD 1.2 billion in milestones, plus tiered royalties for two initial programs, with an option to add a thirdThe agreement will broaden Zealand Pharma’s modality capabilities beyond peptides
- PRRoswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian CancerEngineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical trial underway at Roswell Park Treatment is designed to avoid pre-infusion chemotherapy and its side effects GB-5267 targets MUC16, a biomarker over-expressed in +80% of ovarian tumors BUFFALO, N.Y. and SOMERVILLE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Roswell Park Comprehensive Cancer Center ("Roswell Park") and Generate Biomedicines, Inc. ("Generate") today announced that the first patient has been dosed in a first-in-human clinical trial evaluating GB-5267, an investigational, autologous
- PRGenerate Biomedicines Inc. to Participate in September Investor ConferencesSOMERVILLE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today announced that members of its management team will participate in presentations at the following investor conferences: Cantor Global Healthcare Conference, New York, NY: Wednesday, Sept. 9 at 3:55 p.m. ET Morgan Stanley 24th Annual Global Healthcare Conference, New York, NY: Monday, Sept. 14 at 7:00 a.m. ET Goldman Sachs Life Sciences Symposium, New York, NY: Tuesday, Sept. 15 at 9:05 a.m. ETH.C. Wainwright 28th Annual Global Investment Conference, New York, NY: Wednesday, Sept. 16 at 10:30 a.m. ET Bernstein Insights Healthcare Leaders and Disruptors, New York, NY: Wednesda
- INSIDERDirector Arnold Frances sold $16,002 worth of shares (1,000 units at $16.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.43% to 231,472 units (SEC Form 4)4 - Generate Biomedicines, Inc. (0002100782) (Issuer)
- SECSEC Form 144 filed by Generate Biomedicines Inc.144 - Generate Biomedicines, Inc. (0002100782) (Subject)
- SECSEC Form 144 filed by Generate Biomedicines Inc.144 - Generate Biomedicines, Inc. (0002100782) (Subject)
- SECGenerate Biomedicines Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Generate Biomedicines, Inc. (0002100782) (Filer)
- PRGenerate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business UpdateSOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer) Platform advancements extend across strategic collaborations Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026 SOMERVILLE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Generate Biomedicines Inc. (NASDAQ:GENB) ("Generate") today reported financial results for the seco
- SECGenerate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Generate Biomedicines, Inc. (0002100782) (Filer)
- SECSEC Form 10-Q filed by Generate Biomedicines Inc.10-Q - Generate Biomedicines, Inc. (0002100782) (Filer)
- PRAdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, MassachusettsNewly Constructed Phase 2 now 100% LeasedFurther Solidifies Innovation Park as Boston's Premier Advanced Manufacturing DestinationBOSTON, June 22, 2026 /PRNewswire/ -- IQHQ, Inc. today announced that AdvanCell has signed a long-term ~128,000 square foot lease for the entire 1 Corporate Drive building at Innovation Park, IQHQ's premier life science and advanced manufacturing campus in Andover, Massachusetts. The transaction is one of the largest life science leases in Greater Boston this year and brings the newly constructed Phase 2 of Innovation Park to 100% leased. AdvanCell's decision to locate at Innovation Park after a broad search and competitive process underscores the strength of the
- PRGenerate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare ConferenceSOMERVILLE, Mass., May 28, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) today announced that it intends to participate in the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. A live webcast is expected to be available in the Events and Presentations section of the Company's investor website at investors.generatebiomedicines.com. An archived replay is also expected to be available following the presentation.About Generate:BiomedicinesGenerate (NASDAQ:GENB) is a clinical-stage generative biology company founded at the intersection of machine le
- SECSEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.SCHEDULE 13G - Generate Biomedicines, Inc. (0002100782) (Subject)
- SECSEC Form SCHEDULE 13G filed by Generate Biomedicines Inc.SCHEDULE 13G - Generate Biomedicines, Inc. (0002100782) (Subject)
- PRGenerate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business UpdateSOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advanceClinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (MUC16 armored CAR T); developed in collaboration with Roswell Park Comprehensive Cancer Center Approximately $516.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026 SOMERVILLE, Mass., May 7, 2026 /PRNewswire/ -- Generate Biomedicines, Inc. (NASDAQ:GENB) ("Generate") today reported financial results for the first quarter ended March 31, 2026,
- SECSEC Form 10-Q filed by Generate Biomedicines Inc.10-Q - Generate Biomedicines, Inc. (0002100782) (Filer)
- SECGenerate Biomedicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Generate Biomedicines, Inc. (0002100782) (Filer)
- ANALYSTH.C. Wainwright initiated coverage on Generate Biomedicines with a new price targetH.C. Wainwright initiated coverage of Generate Biomedicines with a rating of Buy and set a new price target of $16.00
- ANALYSTPiper Sandler initiated coverage on Generate Biomedicines with a new price targetPiper Sandler initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $24.00
- ANALYSTMorgan Stanley initiated coverage on Generate Biomedicines with a new price targetMorgan Stanley initiated coverage of Generate Biomedicines with a rating of Overweight and set a new price target of $20.00
GENB FAQ
7 questionsWhat is the latest news on GENB?
In the last 30 days Quantisnow tracked 7 wire items for GENB: 6 press releases and news items and 1 SEC filing. The most recent was published on October 30, 2026.Where does GENB stock trade?
Generate Biomedicines Inc. (GENB) is listed on NASDAQ.What sector and industry is GENB in?
Generate Biomedicines Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Generate Biomedicines Inc. go public?
Generate Biomedicines Inc. (GENB) completed its IPO in 2026.What are analysts saying about GENB?
Generate Biomedicines Inc. has had 6 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1600.00 price target on 2026-04-13. Recent price targets range from $1600.00 to $3000.00.What companies are similar to GENB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GENB side-by-side with any of them on Quantisnow.How can I track GENB on Quantisnow?
Quantisnow aggregates Generate Biomedicines Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GENB to receive live email and push alerts on every new disclosure.